Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Reinholz

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
Breast Cancer Research and Treatment|February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Edith A Perez, Michael F Press, Amylou C Dueck, et al.
BMC Medical Genomics|December 22, 2010
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platformMonica M Reinholz, Jeanette E Eckel-Passow, S Keith Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialEdith A Perez, Monica M Reinholz, David W Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831Amylou C Dueck, Monica M Reinholz, Xochiquetzal J Geiger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab TrialEdith A Perez, E Aubrey Thompson, Karla V Ballman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trialEdith A Perez, Robert B Jenkins, Amylou C Dueck, et al.
Bone|March 18, 2010
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolitesMonica M Reinholz, Shawn P Zinnen, Amylou C Dueck, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
Breast Cancer Research and Treatment|February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Edith A Perez, Michael F Press, Amylou C Dueck, et al.
BMC Medical Genomics|December 22, 2010
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platformMonica M Reinholz, Jeanette E Eckel-Passow, S Keith Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialEdith A Perez, Monica M Reinholz, David W Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831Amylou C Dueck, Monica M Reinholz, Xochiquetzal J Geiger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab TrialEdith A Perez, E Aubrey Thompson, Karla V Ballman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trialEdith A Perez, Robert B Jenkins, Amylou C Dueck, et al.
Bone|March 18, 2010
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolitesMonica M Reinholz, Shawn P Zinnen, Amylou C Dueck, et al.
Pageof 6